Evidence map›Paper›PMID 36765816›Full record

ReviewCancers2023

Childhood Brain Tumors: A Review of Strategies to Translate CNS Drug Delivery to Clinical Trials.

Ruman Rahman, Miroslaw Janowski, Clare L Killick-Cole, William G B Singleton, Emma Campbell, Piotr Walczak, Soumen Khatua, Lukas Faltings, Marc Symons, Julia R Schneider and 11 more

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Cancers, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. The Emerging Role of Ferroptosis in Pediatric Cancer Biology and Therapy.International journal of molecular sciences · 2026
    Review
  2. Review
  3. Review
  4. Review
  5. Review
  6. Review
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors.

Ruman RahmanChildren's Brain Tumor Research Centre, Biodiscovery Institute, University of Nottingham, Nottingham NG7 2RD, UK.ORCID 0000-0002-6541-9983
Miroslaw JanowskiCenter for Advanced Imaging Research, Department of Diagnostic Radiology and Nuclear Medicine, University of Maryland, 655 W. Baltimore Street, Baltimore, MD 21201, USA.ORCID 0000-0001-5261-7975
Clare L Killick-ColeFunctional Neurosurgery Research Group, Translational Health Sciences, Bristol Medical School, University of Bristol, Level 1 Learning and Research Building, Southmead Hospital, Westbury-on-Trym, Bristol BS10 5NB, UK.
William G B SingletonClinical Neurosciences, Translational Health Sciences, University of Bristol & Bristol Royal Hospital for Children, Level 1 Learning and Research Building, Southmead Hospital, Westbury-on-Trym, Bristol BS10 5NB, UK.
Emma CampbellChildren's Brain Tumor Research Centre, Biodiscovery Institute, University of Nottingham, Nottingham NG7 2RD, UK.
Piotr WalczakCenter for Advanced Imaging Research, Department of Diagnostic Radiology and Nuclear Medicine, University of Maryland, 655 W. Baltimore Street, Baltimore, MD 21201, USA.ORCID 0000-0002-3733-3322
Soumen KhatuaDepartment of Pediatrics Hematology/Oncology, Mayo Clinic/Rochester Cancer Center, 200 First St. SW, Rochester, MN 55905, USA.
Lukas FaltingsBrain Tumor Biotech Center, Department of Neurosurgery, Lenox Hill Hospital, Zucker School of Medicine at Hofstra/Northwell, 100 E 77th Street, New York, NY 10075, USA.ORCID 0000-0003-3208-3894
Marc SymonsFeinstein Institute for Medical Research, Zucker School of Medicine at Hofstra/Northwell, 350 Community Dr, Manhasset, NY 11030, USA.
Julia R SchneiderBrain Tumor Biotech Center, Department of Neurosurgery, Lenox Hill Hospital, Zucker School of Medicine at Hofstra/Northwell, 100 E 77th Street, New York, NY 10075, USA.
Kevin KwanBrain Tumor Biotech Center, Department of Neurosurgery, Lenox Hill Hospital, Zucker School of Medicine at Hofstra/Northwell, 100 E 77th Street, New York, NY 10075, USA.
John A BoockvarBrain Tumor Biotech Center, Department of Neurosurgery, Lenox Hill Hospital, Zucker School of Medicine at Hofstra/Northwell, 100 E 77th Street, New York, NY 10075, USA.
Steven S GillFunctional Neurosurgery Research Group, Translational Health Sciences, Bristol Medical School, University of Bristol, Level 1 Learning and Research Building, Southmead Hospital, Westbury-on-Trym, Bristol BS10 5NB, UK.
J Miguel Oliveira3B's Research Group, I3Bs-Research Institute on Biomaterials, Biodegradables and Biomimetics, University of Minho, Headquarters of the European Institute of Excellence on Tissue Engineering and Regenerative Medicine, AvePark, Parque de Ciência e Tecnologia, Zona Industrial da Gandra, Barco, 4805-017 Guimarães, Portugal.ORCID 0000-0001-7052-8837
Kevin BeccariaAPHP, Department of Pediatric Neurosurgery, Necker-Enfants Malades Hospital, 149 Rue de Sèvres, 75015 Paris, France.
Alexandre CarpentierAPHP, Department of Pediatric Neurosurgery, Necker-Enfants Malades Hospital, 149 Rue de Sèvres, 75015 Paris, France.
Michael CanneyCarthera, Laënnec Bioparc, 60A Avenue Rockefeller, 69008 Lyon, France.
Monica PearlDepartment of Diagnostic Imaging and Radiology, Children's National Hospital, 111 Michigan Ave NW, Washington, DC 20010, USA.
Gareth J VealNewcastle University Centre for Cancer, Translational and Clinical Research Institute, Newcastle University, Newcastle Upon Tyne NE1 7RU, UK.ORCID 0000-0002-1897-8678
Lisethe MeijerPrincess Máxima Center for Pediatric Oncology, Heidelberglaan 25, 3584 CS Utrecht, The Netherlands.ORCID 0000-0002-3027-2758
David A WalkerChildren's Brain Tumor Research Centre, Biodiscovery Institute, University of Nottingham, Nottingham NG7 2RD, UK.

Funding

Children with Cancer UK 16-244
6 · The paper itself

Abstract

Brain and spinal tumors affect 1 in 1000 people by 25 years of age, and have diverse histological, biological, anatomical and dissemination characteristics. A mortality of 30-40% means the majority are cured, although two-thirds have life-long disability, linked to accumulated brain injury that is acquired prior to diagnosis, and after surgery or chemo-radiotherapy. Only four drugs have been licensed globally for brain tumors in 40 years and only one for children. Most new cancer drugs in clinical trials do not cross the blood-brain barrier (BBB). Techniques to enhance brain tumor drug delivery are explored in this review, and cover those that augment penetration of the BBB, and those that bypass the BBB. Developing appropriate delivery techniques could improve patient outcomes by ensuring efficacious drug exposure to tumors (including those that are drug-resistant), reducing systemic toxicities and targeting leptomeningeal metastases. Together, this drug delivery strategy seeks to enhance the efficacy of new drugs and enable re-evaluation of existing drugs that might have previously failed because of inadequate delivery. A literature review of repurposed drugs is reported, and a range of preclinical brain tumor models available for translational development are explored.

Indexed as

blood–brain barrierbrain tumor modelchildhood brain tumorscompanion animaldrug deliverydrug repurposingpreclinicalxenograft

Identifiers

PMID36765816
PMCPMC9913389

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.